Ascendis Pharma A (ASND) Tax Provisions (2014 - 2026)

Ascendis Pharma A has disclosed Tax Provisions across 13 years of filings, most recently posting -$793.2 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at -$793.2 million, down 70972.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$809.8 million (down 22132.45% YoY), and the FY2025 annual result was -$46.2 million, down 992.78% from the prior year.
• Tax Provisions came in at -$793.2 million for Q1 2026 at Ascendis Pharma A, down from -$8.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $2.7 million in Q1 2024 to a low of -$793.2 million in Q1 2026.
• The 5-year median for Tax Provisions is -$1.1 million (2025), against an average of -$48.3 million.
• Across the five-year window, Tax Provisions soared 2279.71% in 2022 and tumbled 70972.03% in 2026, its largest moves.
• Ascendis Pharma A's Tax Provisions stood at -$5.5 million in 2022, then fell by 14.19% to -$6.2 million in 2023, then surged by 81.39% to -$1.2 million in 2024, then slumped by 588.43% to -$8.0 million in 2025, then sank by 9837.54% to -$793.2 million in 2026.
• The last three Tax Provisions figures came in at -$793.2 million (Q1 2026), -$8.0 million (Q4 2025), and -$4.2 million (Q3 2025), per Business Quant data.